latest update:
[TrialBase DB]

trial summary · NCT07825857

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

Trial record from the TrialBase DB dataset, status RECRUITING, condition Methamphetamine Use Disorder, sponsored by University of Texas Southwestern Medical Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07825857phase PHASE2enrollment 228start 2026-10-23

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the tolerability, safety, and preliminary efficacy of tirzepatide for the treatment of individuals with moderate or severe methamphetamine use disorder (MtUD). The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD. Participants will undergo study procedures over 32 weeks, including: 1. completing self-assessments 2. undergo brief physical and review of medical and psychiatric history 3. provide urine and blood samples 4. medical management sessions 5. weekly subcutaneous study medication injections

Source record: https://clinicaltrials.gov/study/NCT07825857

Facts

registry idNCT07825857
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionMethamphetamine Use Disorder
sponsorUniversity of Texas Southwestern Medical Center
sponsor classOTHER
enrollment228
start date2026-10-23
primary completion2031-07-01
completion2031-08
results postednot reported

Conditions

  • Methamphetamine Use Disorder

Interventions

  • Tirzepatide
  • Placebo (saline)

Countries

  • United States

Intervention types: DRUG

Work with this record